Sign in →

Test Code CSMRT mSMART Plasma Cell Proliferative Disorder, Pre-Analysis Cell Sorting, Bone Marrow


Specimen Required


Only orderable as a reflex. For more information see MSMRT / Mayo Algorithmic Approach for Stratification of Myeloma and Risk-Adapted Therapy Report, Bone Marrow or MSMRD / Myeloma Stratification and Risk-Adapted Therapy with Reflex to Minimal Residual Disease, Bone Marrow

 

Specimen Type: Redirected bone marrow

Preferred: Yellow top (ACD solution A or B)

Acceptable: Lavender top (EDTA) or green top (heparin)

Specimen Volume: 4 mL


Useful For

Risk stratification of patients with multiple myeloma, which can assist in determining treatment and management decisions

 

Sorting plasma cells for fluorescence in situ hybridization analysis

 

Risk stratification of patients with newly diagnosed multiple myeloma

Method Name

Only orderable as a reflex. For more information see MSMRT / Mayo Algorithmic Approach for Stratification of Myeloma and Risk-Adapted Therapy Report, Bone Marrow or MSMRD / Myeloma Stratification and Risk-Adapted Therapy with Reflex to Minimal Residual Disease, Bone Marrow

 

Flow Cytometric Cell Selection

Reporting Name

MPCDS Pre-Analysis Cell Sorting, BM

Specimen Type

Bone Marrow

Specimen Minimum Volume

1 mL

Specimen Stability Information

Specimen Type Temperature Time Special Container
Bone Marrow Ambient (preferred) 4 days
  Refrigerated  4 days

Reject Due To

Gross hemolysis Reject
Other Fully clotted

Clinical Information

Multiple myeloma is increasingly recognized as a disease characterized by marked cytogenetic, molecular, and proliferative heterogeneity. This heterogeneity is manifested clinically by varying degrees of disease aggressiveness. Multiple myeloma patients with more aggressive disease experience suboptimal responses to some therapeutic approaches; therefore, identifying these patients is critically important for selecting appropriate treatment options.

 

MSMRT / Mayo Algorithmic Approach for Stratification of Myeloma and Risk-Adapted Therapy Report, Bone Marrow classifies patients into either standard or high-risk categories based on the results of 2 assays: plasma cell proliferation and FISH for specific multiple myeloma-associated abnormalities.

Reference Values

Only orderable as a reflex. For more information see MSMRT / Mayo Algorithmic Approach for Stratification of Myeloma and Risk-Adapted Therapy Report, Bone Marrow or MSMRD / Myeloma Stratification and Risk-Adapted Therapy with Reflex to Minimal Residual Disease, Bone Marrow

 

An interpretive report will be provided.

Interpretation

Correlation with clinical, histopathologic and additional laboratory findings is required for final interpretation of these results. The final interpretation of results for clinical management of the patient is the responsibility of the managing physician.

Cautions

No significant cautionary statements

Method Description

Selection of plasma cells using fluorescence activated cell sorting is the most direct and robust method of obtaining relatively pure plasma cell populations for fluorescence in situ hybridization (FISH) assessment.(Instruction manual: BD FACSMelody Cell Sorter User's Guide. Revision 3. BD Biosciences; 03/2020)

Day(s) Performed

Specimens processed Monday through Sunday

Results reported Monday through Friday

Report Available

1 to 11 days

Specimen Retention Time

14 days

Performing Laboratory

Mayo Clinic Laboratories in Rochester

Test Classification

This test was developed and its performance characteristics determined by Mayo Clinic in a manner consistent with CLIA requirements. It has not been cleared or approved by the US Food and Drug Administration.

CPT Code Information

88184-Flow Cytometry; first cell surface, cytoplasmic or nuclear marker

88185 x 5-Flow Cytometry, additional cell surface, cytoplasmic or nuclear marker (each)

LOINC Code Information

Result ID Test Result Name Result LOINC Value
607682 MPCDS Pre-Analysis Cell Sort No LOINC Needed
607688 Final Diagnosis No LOINC Needed